Log in
Enquire now
Nanomix

Nanomix

Nanomix is a Emeryville, California-based medical diagnostics company developing mobile point-of-care diagnostic tools.

OverviewStructured DataIssuesContributors

Contents

nano.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Sensor
Sensor
Nanotechnology
Nanotechnology
Medical diagnostics
Medical diagnostics
Biomedical engineering
Biomedical engineering
Diagnosis
Diagnosis
Proteomics
Proteomics
Technology
Technology
...
Location
San Francisco
San Francisco
Emeryville, California
Emeryville, California
B2X
B2C
B2C
CEO
‌
David Ludvigson
Founder
‌
Alex Zettl, Ph.D.
‌
Marvin L. Cohen, Ph.D.
AngelList URL
angel.co/company/nanomix
Legal Name
Nanomix, Inc.
Legal classification
Corporation
Corporation
Number of Employees (Ranges)
11 – 50
Full Address
5900 Hollis Street, Suite P Emeryville, CA 94608 USA
CIK Number
1,192,958
Investors
Sevin Rosen Funds
Sevin Rosen Funds
EnerTech Capital
EnerTech Capital
180 Degree Capital Corp
180 Degree Capital Corp
Alta Partners
Alta Partners
Apax Partners
Apax Partners
Star Ventures
Star Ventures
DUNS Number
009474888
Founded Date
2000
Total Funding Amount (USD)
49,300,000
Latest Funding Round Date
January 2014
Latest Funding Type
Series D
Series D
Patents Assigned (Count)
24
Wellfound ID
nanomix
Country
United States
United States

Other attributes

Company Operating Status
Active

Nanomix is a company that is known for creating healthcare options for patients that can provide them with rapid and portable diagnostic systems. The company was founded in 2000 by Marvin L. Cohen and Alex Zettl, in Emeryville, California, United States.

The company offers their solutions in order to assist in the treatment and testing of COVID-19. The immunoassay approach Nanomix provides was designed to be handheld, provide rapid results with quantitative information, allowing for a mobile approach to testing diagnostics. Interactions between patients and healthcare professionals is possible at the hospital, via telecommunications, or through alternative point of care solutions with Nanomix.

Nanomix has developed their technologies in order to decentralize disease diagnostics. The assay diagnoses acute kidney injuries, SARS-CoV-2 antigens and antibody tests, cardiac issues, strokes, and traumatic brain injuries. Decentralizing the diagnosis process allows healthcare providers to offer direct and rapid information to their patients.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Nanomix

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.